2019 | BioSenic

Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds

Read more about Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds

Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)

Read more about Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)

Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion

Read more about Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion

Bone Therapeutics announces results of Annual General Meeting

Read more about Bone Therapeutics announces results of Annual General Meeting

Miguel Forte, le nouvel homme fort de Bone Therapeutics (French)

Read more about Miguel Forte, le nouvel homme fort de Bone Therapeutics (French)

Jean Stéphenne: "Bone Therapeutics a énormément changé depuis 2 ans" (French)

Read more about Jean Stéphenne: "Bone Therapeutics a énormément changé depuis 2 ans" (French)

Financial Report H1 2019

Read more about Financial Report H1 2019

2019 Annual Report

Read more about 2019 Annual Report

Bone Therapeutics to participate in upcoming conferences

Read more about Bone Therapeutics to participate in upcoming conferences

Extraordinary General Meeting

Read more about Extraordinary General Meeting

Subscribe to 2019